Ritter Pharmaceuticals, Inc. (RTTR) Reaches $3.09 After 6.00% Down Move; Bulldog Investors Trimmed Royce Value Trust (RVT) Holding By $592,000

April 20, 2018 - By Marie Mckinney

Bulldog Investors Llc decreased Royce Value Trust (RVT) stake by 49.87% reported in 2017Q4 SEC filing. Bulldog Investors Llc sold 37,000 shares as Royce Value Trust (RVT)’s stock declined 5.47%. The Bulldog Investors Llc holds 37,200 shares with $602,000 value, down from 74,200 last quarter. Royce Value Trust now has $1.34 billion valuation. The stock decreased 0.58% or $0.095 during the last trading session, reaching $16.165. About 68,355 shares traded. Royce Value Trust Inc. (NYSE:RVT) has risen 10.45% since April 20, 2017 and is uptrending. It has underperformed by 1.10% the S&P500.

The stock of Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) is a huge mover today! The stock decreased 2.52% or $0.0799 during the last trading session, reaching $3.0901. About 61,598 shares traded. Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) has declined 85.20% since April 20, 2017 and is downtrending. It has underperformed by 96.75% the S&P500.The move comes after 8 months negative chart setup for the $15.27 million company. It was reported on Apr, 20 by Barchart.com. We have $2.90 PT which if reached, will make NASDAQ:RTTR worth $916,020 less.

Investors sentiment increased to 1.88 in Q4 2017. Its up 0.63, from 1.25 in 2017Q3. It improved, as 9 investors sold RVT shares while 23 reduced holdings. 20 funds opened positions while 40 raised stakes. 18.24 million shares or 1.34% less from 18.49 million shares in 2017Q3 were reported. Sei reported 168 shares. Parametric Portfolio Assoc Ltd invested in 111,519 shares or 0% of the stock. Blue Bell Private Wealth Management Limited Liability Company stated it has 347,374 shares or 2.52% of all its holdings. Thompson Siegel And Walmsley Lc invested 0% of its portfolio in Royce Value Trust Inc. (NYSE:RVT). General American invested in 0.28% or 179,416 shares. Invesco Ltd, Georgia-based fund reported 22,666 shares. Cwm Limited Liability Corp owns 791 shares for 0% of their portfolio. Raymond James & Associate, Florida-based fund reported 1.02M shares. The Florida-based Thomas J Herzfeld Advsrs has invested 0.4% in Royce Value Trust Inc. (NYSE:RVT). Paradigm Limited Com holds 24,046 shares. Reilly Advsrs Ltd Llc invested 0% in Royce Value Trust Inc. (NYSE:RVT). 306 are owned by Hudock Cap Group Limited Com. Pring Turner Cap Gp reported 3.29% in Royce Value Trust Inc. (NYSE:RVT). Raymond James Services Advsr stated it has 834,776 shares. Wells Fargo Communications Mn holds 1.62M shares.

Bulldog Investors Llc increased Deutsche Multi (NYSE:KMM) stake by 224,571 shares to 818,416 valued at $7.24M in 2017Q4. It also upped Lazard World Dividend & Income (LOR) stake by 182,747 shares and now owns 205,939 shares. Aberdeen Gtr China Fd (GCH) was raised too.

Analysts await Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) to report earnings on May, 8. They expect $-0.40 EPS, up 71.43% or $1.00 from last year’s $-1.4 per share. After $-1.10 actual EPS reported by Ritter Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -63.64% EPS growth.

Ritter Pharmaceuticals, Inc., a specialty pharmaceutical company, develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The company has market cap of $15.27 million. The Company’s lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b/3 clinical trial for the reduction of symptoms associated with lactose intolerance. It currently has negative earnings. The company's product, RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine.

Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) Ratings Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>